UNSPSC 51112705: Oxaliplatin

This classification denotes a platinum compound with the molecular formula C8H14N2O4Pt, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04ZR38536J, chemically known as (sp-4-3-(cis))-(1,2-cyclohexanediamine-n,n)(ethanedioato(2-)-o,o)platinum but more generally known as oxaliplatin, which bears US NIH Compound Identifier 77994. European Medicines Agency schedules Oxaliplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09490MIG. The term OXALIPLATIN is an International Non-Proprietary Name.

UNSPSC 51112705 Oxaliplatin is a Commodity code for a chemotherapy agent used to treat colorectal and other solid tumors, typically procured by state and local health systems, correctional departments, and public hospital networks. State and local governments acquire oxaliplatin as part of inpatient and outpatient oncology protocols, often through standing purchase agreements, group purchasing organization (GPO) contracts, or individual hospital formulary acquisitions. Procurement occurs through purchasing departments within larger health authority networks and is commonly bundled with other chemotherapy agents under broader pharmaceutical or oncology service contracts rather than as a standalone solicitation.

The source provided contains no recent state or local contract opportunities tagged to this code. Without posted RFP, RFQ, IFB, or ITB records identifying specific issuing bodies, response dates, or transaction values, the geographic spread and current market activity cannot be characterized from available data.